Lisaftoclax

A Bcl-2 inhibitor used in cancer treatment

Lisaftoclax
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Lisaftoclax is a small molecule Bcl-2 inhibitor that is being investigated for its potential use in the treatment of various types of cancer. It is designed to induce apoptosis in cancer cells by inhibiting the Bcl-2 protein, which is often overexpressed in cancerous cells and contributes to their survival.

Mechanism of Action

Lisaftoclax functions by targeting the Bcl-2 protein, a member of the Bcl-2 family of proteins that regulate cell death (apoptosis). Bcl-2 is an anti-apoptotic protein that helps cancer cells evade the normal process of programmed cell death, allowing them to survive and proliferate. By inhibiting Bcl-2, lisaftoclax promotes apoptosis in cancer cells, thereby reducing tumor growth.

Development and Clinical Trials

Lisaftoclax is currently undergoing clinical trials to evaluate its safety and efficacy in humans. These trials are crucial for determining the appropriate dosing, potential side effects, and therapeutic benefits of the drug. The development of lisaftoclax is part of a broader effort to create targeted therapies that specifically attack cancer cells while minimizing damage to normal cells.

Potential Applications

Lisaftoclax is being studied for its potential use in treating several types of cancer, including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, and other hematological malignancies. Its ability to specifically target the Bcl-2 protein makes it a promising candidate for combination therapies, where it can be used alongside other treatments to enhance overall efficacy.

Challenges and Considerations

While lisaftoclax shows promise, there are challenges associated with its development and use. These include managing potential side effects, such as tumor lysis syndrome, which can occur when a large number of cancer cells die rapidly. Additionally, researchers are investigating the potential for resistance to lisaftoclax, which could limit its long-term effectiveness.

Related pages

• Bcl-2 family
• Apoptosis
• Targeted therapy
• Chronic lymphocytic leukemia
• Non-Hodgkin lymphoma